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Measuring Abdominal Obesity: Effects of Height on Distribution of 
Cardiometabolic Risk Factors Risk Using Waist Circumference and Waist-to-
Height Ratio  
 
Accumulating evidence suggests that measures of abdominal obesity outperform BMI in 
predicting diabetes and cardiovascular risk (1–3). However, it is debated which measure of 
obesity should be used. Currently, waist circumference (WC) is most commonly used and 
codefines the metabolic syndrome (4).  
 
Unlike waist-to-height ratio (WHtR), WC does not take differences in height into account. We 
hypothesized that short subjects with a WC at a specified cutoff-point will have more 
abdominal fat and associated cardiovascular risk factors than tall subjects with a WC at the 
same cutoff-point and that this will not be the case if WHtR is used instead of WC. To test 
this hypothesis, we compared the distribution of cardiovascular risk factors according to 
height above and below commonly used cutoffs of WC and WHtR in a cross-sectional study.  
 
We studied 6,971 subjects (mean age 57.6±14.3 years, 4,123 women) from the Diabetes 
Cardiovascular Risk-Evaluation: Targets and Essential Data for Commitment of Treatment 
(DETECT) study, a German, nationally representative cohort of primary care patients (3,5). 
All subjects gave written informed consent, and the study was approved by the local ethics 
committee.  
 
We divided subjects into age- and sex-specific tertiles of height and grouped them according 
to cutoffs for WC and WHtR as suggested in the literature (3,4). Then we compared 
differences in cardiovascular risk factors and the prevalence of at least two factors of the 
metabolic syndrome among height tertiles. We additionally adjusted for age, sex, smoking 
status, and physical activity.  
 
The results are shown in the supplementary table in the online appendix available at 
http://care.diabetesjournals.org/cgi/ content/full/dc10-1794/DC1. If grouped by WC cutoffs 
(102 cm in males and 88 cm in females), individuals in the lowest height tertile, compared 
with the highest tertile, had higher HbA1C, triglycerides, and systolic blood pressure in both 
the high WC group and the low WC group and additionally higher plasma glucose, and LDL 
cholesterol in the low WC group. After adjustment, differences in plasma glucose and LDL 
cholesterol became insignificant.  
 
Grouping by WHtR (age 18 –39 years, 0.50; 40 – 49 years, 0.55; ≥50 years, 0.60) revealed 
higher HDL cholesterol and triglycerides with lower height with differences in triglycerides 
becoming insignificant after adjustment.  
 
In the low WC group, the prevalence of at least two factors of the metabolic syndrome was 
higher in the lowest tertile compared with the highest tertile (crude relative ratio 1.30 [95% CI 
1.16 –1.45]; adjusted relative ratio 1.16 [1.04 –1.29]). There was no difference in prevalence 
of at least two factors of the metabolic syndrome by height in the high WC group or when 
subjects were grouped by WHtR.  
 
We found that short subjects have higher levels of risk factors and a 30% higher prevalence of 
the metabolic syndrome than tall subjects if grouped by WC but not if grouped by WHtR. 
These findings support our hypothesis that risk stratification by WC is biased by height.  
 
It is unlikely that our findings can be attributed to height itself because differences in the 
expected directions were only present if individuals were grouped by WC and not by WHtR.  
 
WHtR is simple to assess. Therefore, we suggest that WHtR instead of WC should be 
implemented in obesity guidelines and in the definition of the metabolic syndrome.  
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